SCHEMBL6779808

SCHEMBL6779808

O=C(O)CC(NC(=O)CNC(=O)c1cccc(NC(=O)NCc2cccc3ccccc23)c1)c1cccnc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 10/20 0.49
ITGAV P06756 7/20 0.49
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SUCNR1 Q9BXA5 2/20 0.46
ITGA2B P08514 3/20 0.45
TSHR P16473 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP2C9 P11712 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ITGB1 P05556 2/20 0.41
ITGA5 P08648 2/20 0.41
MDM4 O15151 1/20 0.41
MDM2 Q00987 1/20 0.41
ITGB5 P18084 1/20 0.40
ITGB6 P18564 1/20 0.40
ITGB8 P26012 1/20 0.40
ITGA8 P53708 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240966 0.90 ITGB3 (0.59) ITGB3ITGAVSUCNR1ITGA2BTSHR
SCHEMBL240965 0.90 ITGB3 (0.59) ITGB3ITGAVSUCNR1ITGA2BTSHR
SCHEMBL7370194 0.89 TSHR (0.58) ITGB3ITGAVMEN1KMT2ASUCNR1
SCHEMBL6777422 0.88 ITGB3 (0.54) ITGB3ITGAVSUCNR1ITGA2BTSHR
SCHEMBL6778483 0.88 SUCNR1 (0.53) ITGB3ITGAVSUCNR1ITGA2BALDH1A1
SCHEMBL6778987 0.86 NPC1 (0.53) ITGB3ITGAVMAPTMEN1KMT2A
SCHEMBL7341225 0.86 SUCNR1 (0.53) ITGB3ITGAVMEN1KMT2ASUCNR1
SCHEMBL7834191 0.84 SUCNR1 (0.50) ITGB3ITGAVSUCNR1ITGA2BTSHR
SCHEMBL6773593 0.84 SUCNR1 (0.50) ITGB3ITGAVSUCNR1ITGA2BITGB1
SCHEMBL6778673 0.84 ITGB3 (0.53) ITGB3ITGAVSUCNR1ITGA2BITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed